Goserelin

Indications

Hormone sensitive cancers of prostate and breast (pre - peri menopausal women); endometriosis, uterine fibroids and endometrial thinning; to assist reproduction; precocious puberty.

Dosage

Administered as a biodegradable implant subcutaneously. Locate implant by ultrasound if need to be removed. Advance prostate cancer: 3.6mg every 4-weeks or 10.8mg every 12-weeks. Advance breast cancer : 3.6mg every 4-weeks. If serum estradiol concentration is not reduced to postmenopausal levels after 8-weeks of therapy, dose increased to 7.2mg (3.5mg implanted to 2 different sites) every 4-weeks. Endometriosis 18years of age or older: 3.6mg every 4-weeks for 6-consecutive months only. Dysfunc

Contra-Indications

Hypersensitivity; to known or suspected pregnancy; lactation; abnormal vaginal bleeding of unknown etiology; children.

Special Precautions

Avoid pregnancy while receiving the drug. Although continuous use of drug usually inhibits ovulation and stop menstruation, contraception is not ensured. Monitor serum testosterone in men and srum estrogen in women.

Side Effects

Temporary increase in symptoms of cancer during initial week of therapy. Bone pain, spinal cord compression, decrease in bone mineral density, osteoporosis, bone fracture, hypercalcemia, stomach upset, hot flushes, headache, dizziness, insomnia, nausea, depression,difficulty in urinating, ureteral obstruction (men), cervical resistance (women), vaginitis, renal impairment. Memory loss, weight gain, swelling and tenderness of breast, acne, bloodpressure changes (hypotension/hypertension). Hirsuti